Unknown

Dataset Information

0

In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs.


ABSTRACT: BACKGROUND: Chordoma, a rare cancer, is usually treated with surgery and/or radiation. However, very limited characterizations of chordoma cells are available due to a minimal availability (only two lines validated by now) and the extremely long doubling time. In order to overcome this situation, we successfully derived a cell line with a shorter doubling time from the first validated chordoma line U-CH1 and obtained invaluable cell biological data. METHOD: After isolating a subpopulation of U-CH1 cells with a short doubling time (U-CH1-N), cell growth, cell cycle distribution, DNA content, chromosome number, p53 status, and cell survival were examined after exposure to X-rays, heavy ions, camptothecin, mitomycin C, cisplatin and bleocin. These data were compared with those of HeLa (cervical cancer) and U87-MG (glioblastoma) cells. RESULTS: The cell doubling times for HeLa, U87-MG and U-CH1-N were approximately 18 h, 24 h and 3 days respectively. Heavy ion irradiation resulted in more efficient cell killing than x-rays in all three cell lines. Relative biological effectiveness (RBE) at 10% survival for U-CH1-N was about 2.45 for 70 keV/?m carbon and 3.86 for 200 keV/?m iron ions. Of the four chemicals, bleocin showed the most marked cytotoxic effect on U-CH1-N. CONCLUSION: Our data provide the first comprehensive cellular characterization using cells of chordoma origin and furnish the biological basis for successful clinical results of chordoma treatment by heavy ions.

SUBMITTER: Kato TA 

PROVIDER: S-EPMC3182904 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature

altmetric image

Publications

In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs.

Kato Takamitsu A TA   Tsuda Akihisa A   Uesaka Mitsuru M   Fujimori Akira A   Kamada Tadashi T   Tsujii Hirohiko H   Okayasu Ryuichi R  

Radiation oncology (London, England) 20110914


<h4>Background</h4>Chordoma, a rare cancer, is usually treated with surgery and/or radiation. However, very limited characterizations of chordoma cells are available due to a minimal availability (only two lines validated by now) and the extremely long doubling time. In order to overcome this situation, we successfully derived a cell line with a shorter doubling time from the first validated chordoma line U-CH1 and obtained invaluable cell biological data.<h4>Method</h4>After isolating a subpopu  ...[more]

Similar Datasets

| S-EPMC7412981 | biostudies-literature
| S-EPMC4370302 | biostudies-literature
| S-EPMC3580060 | biostudies-literature
| 2385953 | ecrin-mdr-crc
| S-EPMC1302029 | biostudies-other
| S-EPMC3361755 | biostudies-literature
| S-EPMC6406899 | biostudies-literature
| S-EPMC4904030 | biostudies-literature
2017-07-26 | GSE86036 | GEO
| S-EPMC6167435 | biostudies-literature